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ABSTRACT 
Role of Altered CCK Response in Bulimia Nervosa 
Sandra L. Hannon-Engel  
Advisor: Barbara E. Wolfe 
The core defining features of bulimia nervosa (BN) are repeated binge eating 
episodes and compensatory purging behavior. The biobehavioral aspects of binge eating 
are complex and not fully understood.  One area of recent interest is the role of the 
satiety-signaling peptide cholecystokinin (CCK). Previous research observed a blunted 
postprandial plasma CCK response in those with BN, therefore suggesting this may be a 
cause, consequence, or maintenance factor in binge eating.  It is unknown whether this 
altered response is due to a state versus trait phenomenon, thus having implications in the 
development of clinical treatment strategies.  
To examine the nature of this altered response, this study assessed whether CCK 
normalizes following remission from BN (RBN). This biobehavioral study utilized a 
comparative design to prospectively evaluate the biological CCK response and the 
corresponding behavioral ratings of satiety and other eating-related sensations in 
individuals with BN (n=10), RBN (n =14), and healthy controls (CON, n=13).  CCK and 
behavioral ratings were assessed at baseline, +15, +30, and +60 minutes following the 
ingestion of a standardized liquid test meal.    
The BN group’s CCK response was blunted and approached significance            
(p =.052) when compared to the RBN and CON groups.  As predicted the RBN and CON 
groups’ CCK response did not significantly differ. This finding supports the premise that 
 
 
CCK may normalize following abstinence from binge and purge (vomit) episodes and 
that this is a state versus trait related phenomenon.   
A significant positive relationship between CCK response and ratings of satiety 
occurred in the RBN group only (r=.59, p<.05). A new and unanticipated finding in the 
BN group was a significant relationship (r=.86, p < .01, two-tailed) between their CCK 
response and urge to vomit.  A greater urge to vomit was reported by those individuals 
who had increased CCK response. Therefore, it is unknown whether the normalization of 
CCK functioning is a protective or liability factor in the stabilization and recovery 
process. Replication studies utilizing a larger sample size are needed to understand the 
role of CCK in recovery and the subsequent development of novel treatment strategies 
for those suffering with BN.
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CHAPTER 1 
INTRODUCTION 
Statement of the Problem 
 Bulimia Nervosa (BN) is a chronic and debilitating eating disorder characterized by 
repeated binge eating episodes followed by purging behavior.  Research suggests that BN 
is at least three times more common in young women than men (Hudson, Hiripi, Pope, & 
Kessler, 2006), culturally-bound (Keel & Klump, 2003), and genetically linked (Bulik et 
al., 2003) with an estimated range of 1%- 4.2% life-time prevalence (Garfinkel et al., 
1995; Hoek & Van Hoeken, 2003; Hudson et al., 2006; Kendler et al., 1991).  Onset of 
the disorder is typically during late adolescence or young adulthood, with an often 
chronic course of illness (Fairburn, Cooper, Doll, Norman, & O'Connor, 2000; Herzog et 
al., 1999; Keel, Mitchell, Miller, Davis, & Crow, 1999), and a substantial economic 
burden (Simon, Schmidt, & Pilling, 2005).  Less than half of affected individuals seek 
treatment (Fairburn et al., 2000; Hoek, 2003), typically for concerns pertaining to 
symptoms of a co-morbid psychiatric diagnosis (Hudson et al., 2006).  The most common 
comorbid psychiatric conditions include: depression (Johnson, Spitzer, & Williams, 
2001) anxiety (Garfinkel et al., 1995; Kaye, Bulik, Thornton, Barbarich, & Masters, 
2004) and substance use disorders (Bulik et al., 2004; Herzog et al., 2006).  Psychosocial 
functioning is poor for those individuals diagnosed with persistent BN (Keller, Herzog, 
Lavori, Bradburn, & Mahoney, 1992) and comorbid Axis II disorders are commonly 
associated with a slower recovery rate (Herzog, Keller, Lavori, Kenney, & Sachs, 1992).  
The most studied and widely accepted form of treatment, Cognitive Behavioral Therapy 
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(CBT), results in less than fifty percent of individuals achieving a full and lasting 
response (Fairburn, 2002).  Overall, long term outcome, recovery, and relapse studies 
have shown that at least one-third of individuals who had previously recovered were 
likely to relapse and/or maintain eating disorder symptoms of clinical severity (Fairburn 
et al., 2000; Herzog et al., 1999).   
 During active illness, this disorder is marked by repeated binge eating and 
compensatory behaviors to prevent weight gain.  The underlying pathophysiologic 
mechanisms that may contribute to this aberrant behavior are complex and poorly 
understood.  Individuals with BN report altered perceptions in hunger, fullness, and 
satiety (Halmi, Sunday, Puglisi, & Marchi, 1989).  Laboratory studies have shown that 
cholecystokinin (CCK), a satiety producing hormone, is blunted in individuals with 
active BN following a meal when compared to matched healthy controls (Devlin et al., 
1997; Geracioti & Liddle, 1988; Pirke, Kellner, Friess, Krieg, & Fichter, 1994). 
Decreased CCK functioning may contribute to impaired satiety and lead to binge eating 
episodes in this patient population.  
Purpose of the Study 
 To help evaluate the extent to which postprandial (after a meal) CCK responses are 
normalized following remission of BN, this project examined CCK responses following a 
test-meal in persons with active BN, remitted BN (RBN), and healthy controls (CON).  
This study provides a further understanding of the possible state-related role of CCK to 
impaired satiety in this patient population. Future studies in these lines of inquiry will 
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help elucidate effective treatment strategies aimed at obtaining and maintaining full 
recovery from BN.      
Definition of Terms 
Satiety: is “the inhibition over hunger and further eating that arises as a consequence of 
food ingestion”(Blundell & Hill, 1993).   
 
Satiation: is depicted as the process that brings an episode of eating to an end, thus 
influencing the size of meals and snacks (Blundell, 2002).  The individual receives 
signals from the brain leading to a feeling of satiety (fullness and satisfaction) which 
leads to the termination of the meal or satiation. 
 
CCK: is a short-term satiety gut neuropeptide that endogenously signals the brain 
processes (through alimentary pathways) that enough food has been eaten.  Because 
CCK-8 is the predominant form used by investigators (Chandra & Liddle, 2007) and 
CCK- receptors in the alimentary pathway only bind to sulfated form (Rehfeld, 2004), 
peripheral plasma concentrations of CCK-8S were measured using a radioimmunoassay 
(RIA) in this study.  This is consistent with previous studies of CCK and satiety and will 
allow for comparison across studies.  
 
Bulimia Nervosa: as defined by the fourth edition text-revised of the Diagnostic 
Statistical Manual of Mental Disorders Fourth Edition-Text Revision (DSM-IV-TR) 
criteria for BN, purging subtype (American Psychiatric Association, 2000).   The criteria 
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identify recurrent binge eating episodes that are characterized by eating (within a 2-hour 
period) an excessive amount of food that is definitely larger than most people would eat 
under similar circumstances. Additionally, during this binge eating episode, individuals 
report a lack of control over eating.  Directly following this episode, individuals engage 
in recurrent inappropriate compensatory behavior to prevent weight gain including: self-
induced vomiting; misuse of laxatives, diuretics, enemas, or other medications; fasting; or 
excessive exercise.  Because self-induced vomiting (purging) is the most prevalent 
compensatory behavior (Reba et al., 2005), only those people who engage in this 
particular behavior will be included in this study.   The DSM-IV-TR criteria further states 
that these aberrant behaviors must occur a minimum of 2 times per week and be present 
for a minimum of 3 months.  Lastly, individuals’ self-evaluation is disproportionately 
based on their current body shape and weight.   
Individuals are further characterized by either purging or nonpurging sub-types.  
Purging type includes those who engage in regular self-induced vomiting or the misuse of 
laxative, diuretics, or enemas.  The nonpurging subtype includes those people who may 
either fast or engage in excessive exercise but do not engage in the aforementioned 
purging subtype behaviors.  For the purpose of this study, purging behavior connotes a 
person diagnosed with BN who engages in self-induced vomiting. 
 
Remitted Bulimia Nervosa: individuals have a history of BN (purging subtype) and no 
history of binge eating, purging behavior, or recurrent inappropriate non-purging 
compensatory behavior during six months prior to study.  These individuals are a major 
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focus of this study and are important in the assessment of whether CCK responsivity 
normalizes following remission from this illness.  If CCK does normalize, this suggests a 
state (acquired) response to binge purge behavior.  If CCK does not normalize in this 
subject group, this suggests a trait (genetic or innate) phenomenon.      
Assumptions 
1. BN individuals consume excessive amounts of food (during a binge episode) in a 
short amount of time, report altered satiety, and subsequently purge consumed 
food. 
2. CCK is a hormone that endogenously signals the brain processes to indicate that 
enough food has been eaten. 
3. CCK functioning in those individuals diagnosed with BN is diminished in 
comparison to matched healthy CON.   
4. CCK is accurately measured as CCK-8S using RIA. 
Research Question 
Is there a significant difference in postprandial CCK response and satiety ratings among 
persons with active BN, RBN, and healthy controls? 
Hypotheses 
 H1. Subjects with BN will have a significantly blunted postprandial plasma CCK 
response compared to the RBN and CON groups. 
 H2. Postprandial plasma CCK response will be significantly positively correlated 
with postprandial visual analog measures of satiety in the RBN and CON groups. 
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Significance of Project  
 Findings of the project provide new information about the integrity of the 
postprandial CCK satiety-signaling in BN.  A central question of this study was whether 
abnormal postprandial CCK response, demonstrated in previous studies of BN, was also 
observed following remission and whether RBN subjects significantly differ from CON 
subjects.  To date, studies have not examined CCK function following remission of BN.  
This study provided an opportunity for the assessment of the extent to which clinical 
remission from BN is associated with normalization of postprandial CCK response.  A 
stable trait related phenomenon could increase the risk and vulnerability of occurrence, 
perturbation, and relapse of this disorder.  However, if CCK responsivity is a state 
phenomenon, this finding points to future intervention and treatment strategies for this 
often chronic, treatment resistant or unresponsive disorder. In summary, this 
determination of post-prandial CCK response in relation to satiety measures will be 
informative to the direction of future research on intervention and treatment strategies for 
BN.
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CHAPTER 2 
Conceptual Framework1 
 
 The biobehavioral aspects of BN are multi-faceted and poorly understood. 
Therefore, a comprehensive theory that encompasses a biobehavioral understanding of 
this debilitating illness is essential in determining appropriate research initiates and 
practice implications. The Roy Adaptation Model (RAM) has been successfully utilized 
in research, practice, and knowledge development.   According to the RAM, nursing’s 
biobehavioral knowledge “balances understanding of the persons as both physiological 
beings in a physical world and as thinking and feeling beings with human experience in a 
cosmic world” (Roy & Andrews, 1999, p. 100).  The person affected by BN is viewed 
from a holistic, expanded and integrated perspective.  This thinking and feeling person is 
considered to possess interrelated parts that comprise a unified whole.  Further, this 
person is considered to possess an adaptive system of control (coping) processes referred 
to as the “regulator” and “cognator” subsystems respectively.  While these coping 
processes serve to maintain adaptation in four critical modes: (a) physiological, (b) self-
concept, (c) role-function, and (d) interdependence, the physiological mode will be the 
major focus of this research.  
 From a simple systems explanation the RAM considers stimuli (inputs) to activate 
control (coping) mechanisms resulting in subsequent behavior (output).  
                                                 
1 The following section was originally developed by this author and the final definitive version was 
published as “Knowledge Development: The Roy Adaptation Model and Bulimia Nervosa” in the Nursing 
Science Quarterly, Vol. 21, No. 2, 126-132 (2008)/ © 2008 SAGE Publications, Inc., All rights reserved 
and can be accessed at http://nsq.sagepub.com/cgi/content/abstract/21/2/126. 
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INPUT  COPING MECHANISM = OUTPUT 
The success of the human system to effectively adapt to stimuli depends on the person’s 
adaptation level, demands of the particular situation, and the condition of the pre-existing 
life processes.  These processes are conceptualized by three levels of functioning: 
integrated, compensatory, and compromised (Roy & Andrews, 1999).  Further 
explication of these specific levels (as related to BN) are depicted in Figure 1.  
The Human as an Adaptive System 
Stimuli 
 Roy depicts three important stimuli (focal, contextual and residual) that subsequently 
activate the coping mechanisms of the human adaptive system.  The focal stimulus calls 
for the immediate and focused attention of the individual.  The person with BN is intently 
focused on and struggles with the thoughts, feelings and behaviors related to the focal 
stimulus, food.  As this struggle persists and the individual attempts to gain control, a 
pattern of binge and purge behavior becomes ingrained.  Contextual stimuli include other 
factors that are currently influencing the person’s ability to respond to the focal stimuli.  
These can include biological vulnerabilities, including altered CCK responsivity and 
impaired satiety.  All other related stimuli that are not evident in the initial assessment 
can be considered residual.  According to the RAM, all stimuli are constantly shifting in 
response to the individual’s environment.  For example, if an individual is suddenly 
confronted with a derogatory comment concerning his or her weight and shape, this once 
residual stimulus can become focal and demand immediate attention.  
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Coping Processes 
 The Roy Adaptation Model (1999) describes the coping processes as those 
internal “innate or acquired ways of interacting with (responding to and influencing) the 
changing environment” (p. 46).  Those processes considered innate are genetically pre-
determined and occur without human intervention (Roy & Andrews, 1999).  This directly 
relates to the central question of this research initiative that investigated whether a 
diminished CCK response to a meal in those with active BN is a genetic trait or a state 
(acquired) phenomenon.  An acquired response to stimuli refers to a learned response 
through repetition.  For instance, purging directly following an episode of binge eating 
effectively rids unwanted calories, food, and abdominal pressure. 
 Additionally, the RAM characterizes the above responses into two subsystems 
called the regulator and cognator subsystems.  The regulator receives automatic innate 
signals from the neural, chemical, and endocrine system channels (see Figure 1).  The 
cognator subsystem “responds through four cognitive emotive channels: perceptual and 
informational processing, learning, judgment, and emotion. Perceptual and informational 
processing includes activities such as selective attention, coding and memory” (Roy & 
Andrews, 1999, p. 46).  In relation to those affected by BN, binge eating and purging 
behaviors become a potent way to manage internal emotional states, resolve challenges to 
personal control, and endure cravings and urge.      
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Behavior   
 The subsequent behavioral response of a person depends on whether the coping 
(control) mechanism is either adaptive or ineffective.  Responses also act as feedback and 
additional input to the overall system.  In BN, recurrent binge and purge behaviors are 
seen as ineffective and compromise the “goals, survival, growth, reproduction and 
mastery of the human being”(Roy & Andrews, 1991, p. 31).  Additional examples and 
multiple linkages between the conceptual model and BN are described in Figure 1.  In 
view of these multiple linkages, it is clear that the RAM is a comprehensive conceptual 
model that may serve as a basis for knowledge and research development in relation to 
BN.
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Figure 1. The Roy Adaptation Model  
OUTPUT  
(Responses or Behaviors) indicates how well the coping mechanisms (internal or 
external) are functioning. Physiological & psychosocial behavior indicates whether the 
coping mechanisms are able to adapt to the stimuli affecting them. 
 
1. Chronic binge & purge (vomit) behavior (bulimia nervosa) can be viewed as 
ineffective, disrupted & compromised responses that threaten survival, growth, 
reproduction & mastery.  Behavior is observed and measured in lab studies with 
collaborating subjective verbal and diary accounts of amount eaten and subsequent 
vomiting behavior. 
 
2. Postprandial CCK response under normal circumstances represents an innate 
compensatory mechanism that brings eating behavior to its end. However in bulimia 
nervosa, CCK response is diminished (ineffective, compromised regulator response) as 
measured by radioimmunoassay in laboratory studies.  The Regulator subsystem receives 
inadequate input or stimulus from the endocrine and neurological system channels & 
processes.  
 
3. Altered satiety can be further designated as an ineffective & compromised regulator 
and cognator response (observed & measured in amount eaten in lab, and subjectively 
reported using VAS). 
INPUTS  
(Stimuli & Adaptation 
level) 
Focal- food, chronic binge 
purge episodes  
Contextual-bulimia nervosa, 
biological vulnerabilities 
(diminished CCK). cognator 
deficits 
Residual- Perceptions of 
implicit and explicit cultural 
expectations about body 
weight and shape from peers, 
family and society.  CONTROLS 
INPUT 
Adaptation Problems 
 Ineffective hormone 
regulation 
 Instability of hormone system 
loops 
 Ineffective coping strategies 
for altered means of 
ingestion. 
 
*Interventions are aimed at 
influencing the output response to 
promote adaptation. 
 
CONTROLS  
(Regulator & Cognator Subsystems) are internal processes 
or control (coping) mechanisms (innate or acquired). Stimuli 
activate the coping mechanisms producing adaptive and or 
ineffective behavior. 
Regulator 
Input from nervous, circulatory, endocrine system channels. 
Cognator 
Input from internal and external: psychological, social, 
physical, and physiological factors.  
OUTPUT 
*Italicized words indicate a relationship to BN that can 
be viewed as ineffective and not compatible with the 
health goals of the human being. 
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Review of the Literature2 
 A review of the literature begins over 25 years ago when BN was first described by 
Russell (1979) as an “ominous variant” of anorexia nervosa (AN).  In his initial account, 
he describes this “bulimic” group as having core eating disordered beliefs about weight 
similar to that of AN.  However, unlike those with AN, who severely restrict food 
consumption, persons with BN have striking and distinct symptom patterns including an 
irresistible urge to overeat followed by self-induced vomiting (Russell, 1979).  Since that 
time, BN has received increased research and clinical attention due to the severe and 
chronic nature of this disorder (Keller et al., 1992). 
Symptom Patterns and Clinical Characteristics of BN 
 The DSM-IV-TR identifies the cardinal feature of BN as binge eating, characterized 
by a “loss of control” during repeated episodes of eating excessively large amounts of 
food.  This is followed by inappropriate purging or nonpurging compensatory behaviors 
(American Psychiatric Association, 2000).  Purging behaviors include self-induced 
vomiting, laxative abuse, diuretic abuse, and misuse of enemas.  Nonpurging behaviors 
include fasting, strict dieting, and / or excessive exercising in an effort to maintain or lose 
weight.  To meet diagnostic criteria, binge eating and purging behaviors must occur at a 
minimum frequency of two times per week over the course of three months. 
                                                 
2 The following section was originally developed by this author and the final definitive version was 
published as “Regulating Satiety in Bulimia Nervosa: The Role of Cholecystokinin”  in Perspectives in 
Psychiatric Care. 2011 doi: 10.1111/j.1744-6163.2011.00304.x  © 2011 Wiley Periodicals Inc, 
 All rights reserved and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.1744-
6163.2011.00304.x/abstract;jsessionid=510763C4440675CA1FAC2B732CD6B816.d01t04 
OUTPUT  
(Responses or Behaviors) indicates how well the coping mechanisms (internal or 
external) are functioning. Physiological & psychosocial behavior indicates whether the 
coping mechanisms are able to adapt to the stimuli affecting them. 
 
1. Chronic binge & purge (vomit) behavior (bulimia nervosa) can be viewed as 
ineffective, disrupted & compromised responses that threaten survival, growth, 
reproduction & mastery.  Behavior is observed and measured in lab studies with 
collaborating subjective verbal and diary accounts of amount eaten and subsequent 
vomiting behavior. 
 
2. Postprandial CCK response under normal circumstances represents an innate 
compensatory mechanism that brings eating behavior to its end. However in bulimia 
nervosa, CCK response is diminished (ineffective, compromised regulator response) as 
measured by radioimmunoassay in laboratory studies.  The Regulator subsystem receives 
inadequate input or stimulus from the endocrine and neurological system channels & 
processes.  
 
3. Altered satiety can be further designated as an ineffective & compromised regulator 
and cognator response (observed & measured in amount eaten in lab, and subjectively 
reported using VAS). 
INPUTS  
(Stimuli & Adaptation 
level) 
Focal- food, chronic binge 
purge episodes  
Contextual-bulimia nervosa, 
biological vulnerabilities 
(diminished CCK). cognator 
deficits 
Residual- Perceptions of 
implicit and explicit cultural 
expectations about body 
weight and shape from peers, 
family and society.  
CONTROLS 
INPUT 
Adaptation Problems 
 Ineffective hormone 
regulation 
 Instability of hormone system 
loops 
 Ineffective coping strategies 
for altered means of ingestion. 
 
*Interventions are aimed at 
influencing the output response to 
promote adaptation. 
 
CONTROLS  
(Regulator & Cognator Subsystems) are internal processes 
or control (coping) mechanisms (innate or acquired). Stimuli 
activate the coping mechanisms producing adaptive and or 
ineffective behavior. 
Regulator 
Input from nervous, circulatory, endocrine system channels. 
Cognator 
Input from internal and external: psychological, social, 
physical, and physiological factors.  
OUTPUT 
*Italicized words indicate a relationship to BN that can be viewed as ineffective 
and not compatible with the health goals of the human being. 
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 A pervasive devalued self-worth, including loathing of body weight and body shape, 
is characteristic of BN.  Common premorbid characteristics of impulsivity (Wolfe, 
Jimerson, & Levine, 1994), dysregulated emotions, anxiety, depression (Brewerton et al., 
1995; Kaye et al., 2004), low self-esteem, early menarche, dieting and critical comments 
about eating (Fairburn, Welch, Doll, Davies, & O'Connor, 1997) may contribute to the 
vulnerability and expression of this disorder.  Individual risk factors include genetic and 
familial (Kassett et al., 1989) vulnerabilities to dieting, obesity, psychiatric disorders and 
substance misuse disorders (Fairburn & Harrison, 2003).  Individuals affected by this 
disorder are likely to maintain a normal weight despite fluctuations and a decreased 
metabolic rate (Birketvedt et al., 2006; Obarzanek, Lesem, Goldstein, & Jimerson, 1991).  
Food restriction and dieting generally precede episodes of binge eating (Beumont, 2002; 
Pyle, Mitchell, & Eckert, 1981; White, 2000) and are regularly attempted but interrupted 
by repeated gorges. 
 Comorbid medical conditions ensue with persistent illness.  Tooth enamel can 
become eroded secondary to the direct repeated exposure to gastric acids following a 
vomiting episode (Milosevic, 1999).  The most frequent compensatory behavior, self-
induced vomiting (Reba et al., 2005), can further compromise electrolyte status, requiring 
careful monitoring of specific laboratory values to avert complications (Wolfe, Metzger, 
Levine, & Jimerson, 2001).  Surprisingly, even when individuals affected by BN present 
for routine and/ or related medical care, this illness often goes undetected (Johnson et al., 
2001) as patients may under report symptoms secondary to shame, guilt and / or a desire 
to retain this aberrant eating behavior. 
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Bulimia Nervosa and Binge Eating 
 For over twenty years, laboratory studies have been a reliable and valid method to 
measure eating behavior in BN (Gosnell et al., 2001; Kissileff, Walsh, Kral, & Cassidy, 
1986; Mitchell, Crow, Peterson, Wonderlich, & Crosby, 1998).  Studies have effectively 
established dependable paradigmatic protocols within a controlled environment to 
objectively understand factors contributing to the termination of eating once it has begun 
(Kissileff, 1992).  Initial reports from patients with BN indicate an inability to discern 
fullness at the end of a normal meal and eating patterns that alternate between severe 
restriction and binge eating (Mitchell, Hatsukami, Eckert, & Pyle, 1985; Pyle et al., 
1981).  While self-reports of food consumption by those with BN appeared dramatic 
(Mitchell & Laine, 1985), studies show a direct correlation between subjective accounts 
and laboratory measurement of food intake (Walsh, Kissileff, Cassidy, & Dantzic, 1989). 
Clinical laboratory studies, using both a multi-item and single-item test meal, show that 
patients with BN consume a significantly larger amount of food compared to controls 
(Guss, Kissilef, Walsh, & Devlin, 1994; LaChaussée, Kissileff, Walsh, & Hadigan, 1992; 
Walsh, Kissileff, & Hadigan, 1989).  In sharp contrast to healthy controls, despite eating 
quantifiably larger amounts of food, patients with BN reported less fullness and displayed 
increased motivation to eat as the meal progressed (Kissileff et al., 1996).  These studies 
demonstrate a clear aberration that may serve to perpetuate this incapacitating disorder. 
 The macronutrient composition of meal choice by BN subjects has generally 
remained comparable to controls.  However, a trend towards dessert and snack foods has 
been described (Rosen, Leitenberg, Fisher, & Khazam, 1986).  A carbohydrate craving 
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has been suggested as a driving force in the perpetuation of binge eating; however, this 
hypothesis remains inconclusive (Hadigan, Kissileff, & Walsh, 1989).  In laboratory 
studies of eating behavior, BN subjects consumed far fewer calories when instructed not 
to binge in comparison to controls (Hadigan et al., 1989), underscoring that persons with 
BN may regularly restrict when not engaged in a binge eating episode.  One plausible 
explanation is that due to a lack of inhibitory controls in BN, patients artificially 
terminate meals in contrast to allowing the naturally occurring mechanisms of satiety to 
affect both meal size and duration (Walsh, Kissileff, & Hadigan, 1989). 
Binge Eating and Satiety 
Satiety refers to “the inhibition over hunger and further eating that arises as a 
consequence of food ingestion” (Blundell & Hill, 1993).  Satiation is a term typically 
used to describe “the process that brings a period of eating to an end and thus influences 
the size of meals and snacks” (Blundell, 2002).  A functional satiety system (see Figure 
2) can be best described as a complex integrative central and peripheral signaling 
network of positive and negative feedback mechanisms that work to maintain energy 
homeostasis (Smith & Geary, 2002).  Positive feedback signals are initiated by feeding 
behavior.  In response, a supposed symmetrical inhibitory or negative feedback signal, 
requiring greater potency, terminates the episode of eating (Smith & Gibbs, 2002b). If 
there is a dysregulation in the relative potency of the negative feedback signaling 
mechanism, meal size and duration can be increased.  Thus, binge eating may reflect a 
relative dysregulation in the negative feedback mechanism of the satiety system (Jarosz 
& Metzger, 2002). 
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                                    Figure 2. Normal eating behavior  
 
 
Overview of CCK 
 One key inhibitory component of eating behavior is the gastrointestinal hormone 
cholecystokinin (Smith, 2002).  CCK was originally discovered in 1928 (Ivy & Oldberg) 
for its ability to contract the gallbladder, and later found to stimulate pancreatic exocrine 
secretion (Harper & Raper, 1943).  Additional physiological actions include regulation of 
gastric emptying and induction of satiety.  In a highly synchronized manner, CCK 
regulates the intake, digestion, and absorption of nutrients (Liddle, 1997). 
 CCK is produced by the enteroendocrine cells located in the proximal mucosa of the 
small intestine (Liddle, 1997).  CCK producing cells can be found in the small intestine, 
vagal afferent nerve fibers, and brain (Moran, 2000).  CCK-1 receptors (previously 
identified as A-alimentary) are primarily located in the gastrointestinal system whereas 
CCK-2 receptors (previously known as B-brain) are located in the central nervous system 
(CNS) (Moran, Robinson, Goldrich, & McHugh, 1986).  It is the interactions of the 
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CCK-1 receptors that are thought to contribute to satiety signaling (Moran, Ameglio, 
Schwartz, & McHugh, 1992).  The original bioactive form was isolated as CCK-33 from 
the small intestine, while other molecular forms were identified in the brain and plasma 
across species (Rehfeld, 2004).  In mammals, CCK molecules range in bioactive forms 
from CCK-8 to 58.  However, it is predominately CCK-58, 33, 22, and 8 that are released 
into plasma (Rehfeld, 1998)  
 The signal pathway (see Figure 3) that is involved with satiety, and central to this 
study, begins with a robust and predictable CCK post-ingestive response to nutrients 
(Smith & Geary, 2002).  After chyme enters the proximal duodenum through relaxation 
of the pyloric sphincter, CCK is released from the lumen mucosa into the peripheral 
bloodstream (Smith & Gibbs, 2002a).  It then interacts with CCK receptor-1 along the 
vagus nerve projecting onto the nucleus tractus solitarius (NTS) of the hindbrain 
(Blundell & Hill, 1993; Moran, Norgren, Crosby, & McHugh, 1990).  Further influence 
extends to the arcuate nucleus of the hypothalamus and the paraventricular nucleus 
(PVN) (Blundell, 2006; Rehfeld, 2004).  This higher order integration evaluates 
inhibitory signals and metabolic state to determine energy storage needs for regulation, 
whereas the NTS primarily controls the amount of food eaten (Havel, Larsen, Cameron, 
Conn, & Freeman, 2000; Hellstrom et al., 2004).  Therefore, if this pathway is altered due 
to a diminished CCK response, it follows that individuals with BN would consume 
excessive amounts of food. 
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                                                 Figure 3. CCK signal pathway3 
 
CCK and Satiety: Preclinical Studies 
 Pre-clinical studies have been essential in demonstrating CCK as an integral 
component of the satiety system.  These studies have shown that intravenous 
administration of CCK induced satiety in canine (Sjodan, 1972) and rats (Gibbs, Young, 
& Smith, 1973).  Additionally, intraperitoneal injection of CCK during sham feeding in 
the rat not only stopped feeding but elicited the complete behavioral sequence of satiety 
                                                 
3 From “Cellular Warriors at the Battle of the Bulge,” by J. Marx, 2003, Science, 299, p. 846-849.  
Reprinted with permission of the author. 
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(Antin, Gibbs, Holt , Young, & Smith, 1975).  A total abdominal vagotomy in the rat 
blocked the satiety effects of exogenous CCK administration (Smith, Jerome, Cushin, 
Eterno, & Simansky, 1981), confirming that the abdominal vagal afferent nerve fibers 
mediate the inhibitory signals to the hindbrain.  In summary, CCK interacts with the 
vagus nerve, which sends a robust signal to the hindbrain for the termination of a meal. 
Again, it is evident that a reduction in CCK results in a weak signal that fails to 
discontinue a meal, contributing to increased quantity of food intake.
CCK and Satiety: Clinical Studies 
 In humans, intravenously infused administration of CCK versus saline in a double 
blind experimental design, yielded a decreased appetite in young normal weight men 
(n=8) and women (n=8) (Stacher, Bauer, & Steinringer, 1979) and an earlier termination 
of the meal, without changes in the rate of eating or complaints of side effects in twelve 
healthy lean (Kissileff, Pi-Sunyer, Hornton, & Smith, 1981) and eight obese (Pi-Sunyer, 
Kissileff, Thornton, & Smith, 1982) men.  Additionally, postprandial visual analog 
satiety ratings were positively correlated with CCK responses in seven healthy males 
(Holt, Brand, Soveny, & Hansky, 1992).  While initial studies showed administration of 
CCK reduces meal size and duration, studies using a CCK receptor-1 antagonist showed 
an increase in caloric intake and feelings of hunger (Beglinger, Degen, Matzinger, 
D'Amato, & Drewe, 2001).  In a preliminary report, (Nolan, Guss, Liddle, Pi-Sunyer, & 
Kissileff, 2003) a liquid test meal was shown to significantly stimulate CCK release, with 
subsequent decreased hunger ratings and increased fullness ratings in healthy males and 
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females.  The above evidence establishes CCK as a satiety agent (Smith, 1998) and 
provides verification that it can be adequately stimulated by a liquid meal in a controlled 
laboratory setting. 
CCK and Satiety: BN 
 Individuals affected by BN consistently exhibit altered perceptions of hunger, 
fullness, and satiety (Halmi et al., 1989).  A dysregulated satiety system fails to signal 
and subsequently inhibit intake of food (Devlin et al., 1997).  CCK’s post prandial 
plasma measurement, compared to controls, shows a blunted response in individuals with 
BN (Devlin et al., 1997; Geracioti & Liddle, 1988; Pirke et al., 1994).  It has been 
postulated that patients with BN have a compilation of gastrointestinal dysfunctions (see 
Figure 4) that serve to diminish the responsiveness of post-ingestive CCK release 
(Hadley & Walsh, 2003; Walsh, Zimmerli, Devlin, Guss, & Kissileff, 2003). Subjects 
with BN have been found to have an enlarged gastric capacity, decreased accommodation 
reflex, diminished sensitivity to distension, and slowed gastric emptying as compared to 
matched healthy controls (Zimmerli, Walsh, Guss, Devlin, & Kissileff, 2006).  An 
enlarged gastric capacity (secondary to repeated binges) (Geliebter & Hashim, 2001), 
may take longer to fill, thereby delaying entry into the proximal small intestine.  This 
slowed gastric emptying (Geliebter et al., 1992) could confound a robust release of CCK 
into the periphery (Devlin et al., 1997). 
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 In review, individuals afflicted with BN and altered satiety are largely defined 
indirectly by their comparison to matched healthy controls and thus viewed to maintain 
the following attributes: 
1. Feel out of control while repeatedly consuming a significantly greater amount of food. 
2. Rate and desire to binge eat accelerates instead of decelerates as the meal progresses. 
3. Report feeling less, rather than more, satiated, after eating excessively large amounts 
of food. 
4. Exhibit altered perceptions of hunger and fullness. 
5. Feel more anxious, depressed, sick and less relaxed during an episode of binge eating. 
6. Exhibit a compilation of gastrointestinal dysfunctions. 
7. Demonstrate diminished CCK post-prandially. 
 
REPEATED BINGES 
 
 
Enlarged gastric capacity 
 
 
Decreased accommodation reflex 
 
 
 
Diminished sensitivity to distension 
 
 
 
Slowed gastric emptying 
 
 
 
DIMINISHED CCK RESPONSE 
 
Figure 4. Compilation of gastrointestinal dysfunctions in BN 
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Influencing CCK   
 In a preliminary exploration of five individuals with BN (studied before and after 
starting a tricyclic antidepressant) an initial improvement in CCK response was shown 
following a liquid test meal (Geracioti et al., 1989).  While the mechanism of this finding 
is not fully understood, as it may be related to a number of interacting influences, 
including the limitations of a small sample size, the study points to the importance of 
examining the underlying mechanism of CCK responsivity in a larger group of carefully 
characterized medication-free RBN individuals. 
Importance of the Knowledge to be Gained 
 Bulimia nervosa is a serious psychiatric disorder often associated with a chronic 
course of illness, significant psychosocial distress, and potentially severe medical 
consequences.  Although the etiology remains elusive, previous findings suggest that 
altered regulation of CCK function may contribute to abnormal eating patterns and meal 
size in persons affected by this disorder.  Results of this project evaluate the extent to 
which postprandial CCK responses are normalized following remission of BN, 
contributing an increased understanding of the possible state-related role of CCK in 
relation to satiety in this disorder.  Further understanding of this role has the potential for 
informing future interventions that may target CCK function, enhance satiety signaling, 
and decrease the binge eating episodes in BN.
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CHAPTER 3 
METHODOLOGY 
Study Design 
 This clinical research study used a comparative design to prospectively assess the 
integrity of the CCK-mediated satiety signaling in persons with RBN, BN and healthy 
controls (CON). 
Subjects 
 This project included a convenience sample of women with RBN (n=14), BN (n=10), 
and healthy female volunteers (n=13).  A control group (CON) was included to allow for 
replication of previously reported findings.  This latter group of individuals was carefully 
screened to rule out a diagnosis of a current or past DSM-IV-TR Axis I diagnosis, 
including eating disorders.  Subject group inclusion criteria are as follows: 
RBN: 1) History of BN, purging (vomiting) subtype, as defined by the DSM-IV-TR 
(American Psychiatric Association, 2000).  2) No history of binge eating, purging 
behavior, or recurrent inappropriate non-purging compensatory behavior during six 
months prior to study (consistent with previous research). 
BN:  1) DSM-IV-TR criteria for BN, purging subtype (full definition, page 3). Patient 
groups were free of all medications (except birth control), supplements, probiotics for at 
least eight weeks prior to study. 
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CON: 1) Free of current or past history of DSM-IV-TR eating disorder; 2) not actively 
engaged in dieting behavior for the purpose of weight loss as measured by a score of  
< 16 on the Restraint Scale (Polivy, Herman, & Howard, 1988). 
All Subjects: 1) age 18-45 years; 2) body mass index (BMI) between 19 - 26 kg/m2 
(considered normal weight); 3) gender, female; 4) in good medical health, free of known 
medical conditions or medication treatment (except for birth control) or any supplements 
or probiotics that may have an effect on gastrointestinal function ; 5) not pregnant or 
nursing an infant in past six months; and, 6) free of alcohol use for 72 hours prior to 
study.  This set of inclusion criteria is similar to those used in previous investigations of 
CCK functioning (Devlin et al., 1997; Keel, Wolfe, Liddle, De Young, & Jimerson, 
2007) thus allowing comparison with previous findings. 
Setting 
 Subjects who met initial participant inclusion criteria (determined by telephone 
screening) were scheduled for a screening visit conducted by the principal investigator 
(PI).  Screening visits occurred in a private interview room designated in the School of 
Nursing at Boston College or an outpatient interview room at the NIH funded Clinical 
Research Center (CRC) at Beth Israel Deaconess Medical Center (BIDMC).  This 
hospital is an academic and clinically research driven environment. 
 A second study visit was conducted in an outpatient room at the CRC at BIDMC.  
The CRC is a fully staffed unit providing inpatient and outpatient services.  This study 
utilized CRC outpatient and core lab facilities.  A range of research trained staff 
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including nursing personnel, dieticians, lab technicians and administrative staff supported 
the operations of this study.  Directly following blood sample collection, specimens were 
centrifuged (spun at 1500xg for 15 min. at 4˚C) and clear plasma was transferred by the 
PI, lab personnel or nursing staff into the appropriate polypropylene tubes and stored in a 
freezer at -70˚c at BIDMC until time of assay. 
Procedures 
 Recruitment and screening.  RBN subjects, BN subjects, and healthy controls were 
recruited using study flyers and postings strategically positioned at approved community 
and university communication sites (e.g., college postings, community centers) and in 
accordance with the IRB protocol.  Additionally, this study was posted in select 
university magazines, newspapers and internet sites (e.g. Craig’s list, Facebook).  In 
addition to basic inclusion criteria, advertisements indicated that each subject would 
receive thirty- dollars ($30) at the completion of the screening visit and seventy ($70) at 
the completion of the study visit. The PI conducted 108 pre-screening telephone 
interviews and subsequently scheduled 68 qualified subjects for a screening visit at 
Boston College or the BIDMC CRC.  Including both the screening and the study visits 
the PI completed a total of 106 in person visits.   
 Screening visit.  During this visit, subjects received a detailed explanation of study 
procedures from the PI and read the informed consent document (Appendix B).  Directly 
following, the subjects explained their understanding of the study to the both the PI and 
the witness per protocol.  Throughout this process the subjects had the opportunity to ask 
questions prior to signing the informed consent document.  The initial interviews 
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proceeded only after written informed consent was obtained.  Screening assessment 
procedures involved the administration of the Structured Clinical Interview for DSM-IV 
Axis I Disorders (First, Spitzer, Gibbon, & Williams, 2010).  Subjects were asked to 
complete the following self-rated scales: Eating Disorder Examination- Questionnaire 
(EDE-Q 6.0; Mond, Hay, Rodger, Owen, & Beumont, 2004) , the Restraint Scale (Polivy 
et al., 1988) to determine the level of current dieting behavior, he Beck Depression 
Inventory – II (BDI-II; Beck, Steer, & Brown, 1996) was utilized to assess level of 
depression and need for clinical referral.  Interviews were conducted by the PI and 
assessment materials were evaluated at time of completion in the event there was a need 
for referral.  Additional data collected included fluctuations in body weight, dietary 
patterns, and medical history.  An initial assessment of height and body weight was 
obtained.  Following the screening assessments, subjects were asked to consume the 
standardized liquid test meal (described below) in order to allow them to acclimate to the 
study procedure, as well as to assess the acceptability and taste-preference (Peryam & 
Pilgrim, 1957). 
 Outpatient study visit.  Following the screening visit, the PI scheduled eligible 
subjects for an outpatient study visit at the BIDMC CRC.  Subjects were scheduled 
during the morning hours and were asked to arrive following an overnight fast.  After 
review of informed consent, subjects received a brief updated assessment of psychiatric 
and medical symptoms by the PI.  Nursing personnel, using an anthropometric station 
and calibrated metabolic scale, obtained a measurement of height and weight (reported in 
Table 3) while the subject wore two hospital gowns.  Based on these results, the PI 
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calculated the subject’s BMI using http://www.nhlbisupport.com/bmi/.   The study visit 
proceeded only if the subject met BMI inclusion parameters of 19-26kg/m2 .   In addition, 
orthostatic vital signs and a urine sample for a pregnancy screen were conducted.  At the 
suggestion of an NIH reviewer, baseline measure of aggression (Aggression 
Questionnaire; Buss & Perry, 1992) was collected to obtain descriptive characteristics 
relative to anger and hostility.   
 Following placement of an intravenous catheter (in the forearm) by CRC nursing 
personnel, subjects had a 15 minute stabilization period after which a baseline blood 
sample was drawn for measurement of plasma CCK.  Approximately 5 minutes following 
the blood draw, subjects were asked to consume a standardized liquid test meal in the 
course of the next five minutes.  The standardized liquid test meal consisted of 600 ml of 
Ensure Plus ® (approximately 900 Kcal, 30% fat, 15% protein, and 55% carbohydrate) 
which has been used successfully in previous studies in this patient population (Devlin et 
al., 1997; Keel et al., 2007).  The use of the standardized liquid test meal (600ml) was 
selected based on previous research showing that ingestion of 600 ml had a larger effect 
(Cohen’s d = 1.47)  on differences in plasma CCK response in patients with BN (n=8) in 
comparison to controls (n=10) (Devlin et al., 1997). Data collection time points were 
consistent with those used in previous studies (Devlin et al., 1997) to enable cross 
comparisons. Subjects were asked to complete a set of 100mm visual analog scales 
(VAS) that assessed feelings of hunger, satiety, fullness, anxiety, depression, desire to 
binge, and desire to purge at the time of blood sample collection.  Additionally, subjects 
received a side effect checklist (SEC) at the same time points of the VAS ratings. This 
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allowed for the monitoring of symptoms before and after the test meal (Figure 5.).  The 
study visit lasted up to two hours.  
                                                      Approx. 5 min 
                              
       
IV 15 min Baseline Test  +15 min.  +30min +60 min. 
placement stabilization 
period 
Blood draw 
VAS 
SEC 
Meal 
(w/in 5 min) 
 
 
Blood drawn, VAS, and SEC 
 from end time of test meal     
 
Figure 5. Timeline for pre and post ingestion of standardized test meal. 
 
Blood samples were kept on ice for 5 minutes in tubes prepared with 
ethylenediaminetetraacetic acid (EDTA) and aprotinin (Trasyol) before cold 
centrifugation (1500xg) for 15 minutes.  The plasma was pipetted into cryo-microtubes 
and stored at -70ºC until batch assayed.  Prior to analyses samples were packed in dry ice 
according to BIDMC required shipping and handling procedures and sent overnight to 
KMI, incorporated diagnostics laboratory testing center in Minneapolis, MN.  Laboratory 
analyses were performed (in duplicate in the same assay, along with standardized 
controls) on coded samples by technicians blind to diagnosis and other clinical 
information on individual subjects.  Plasma CCK concentrations (CCK-8S) were 
measured using a radioimmunoassay (RIA) kit lot: NS2323US from EuroDiagnostica.  
The RIA  method developed by Rehfeld (1998)  was chosen due to its’ high degree of 
accuracy, sensitivity, specificity, in the plasma measurement of CCK, and its’ wide use 
Study visit  
completed 
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and acceptance by investigators. This procedure is consistent with previous studies of 
CCK and satiety (Geliebter, Yahav, Gluck, & Hashim, 2004; Pirke et al., 1994).  For this 
kit, CCK intra-assay coefficient of variation (CV) is 4.4 pmol/L (5.5%) and inter-assay 
coefficient of variation is 4.2 pmol/L (13.7%).  Normal fasting level of CCK is ≤1.12 
pmol/L.  Assay sensitivity is (LDC) = 0.3 pmol/L. The CCK values supplied by KMI 
were the mean values of the duplicate RIA analyses. 
Instruments 
 Instruments used in this study are listed in Table 1.   Specific psychometric properties 
for each are described below. 
Table 1. List of Instruments    
SCREENING VISIT 
 Structured Clinical Interview for DSM-IV Axis I Disorder, Research Version, 
Version 2.0 Patient Edition (SCID-I/P) 
 Eating Disorder Examination- Questionnaire  (EDE-Q 6.0) 
 Beck Depression Inventory-II (BDI-II). 
 Restraint Scale, Revised 
STUDY VISIT 
 Beck Depression Inventory-II (BDI-II). 
 The Aggression Questionnaire 
 Hunger, Satiety, Pleasantness of Foods Visual Analog Scales 
      fullness, anxiety, depression, desire to binge, and desire to purge 
 Side Effect Checklist 
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 Structured Clinical Interview for DSM-IV Axis I Disorder, Research Version,  Patient 
Edition (SCID-I/P, 1/2010 revision) © Biometrics Research Department.  The SCID-I/P 
(First et al., 2010) is a structured interview administered by a clinician for the purpose of 
making a DSM-IV Axis I diagnosis. During this study, the PI conducted each interview at 
the screening visit.  Modules of this version include psychotic disorders, mood disorders, 
substance use disorders, anxiety disorders, somatoform disorders, eating disorders, and 
adjustment disorder.  Language is targeted to an 8th grade education.  Kappa values vary 
among diagnoses, but are reported to be generally comparable to other diagnostic 
measurements including the Schedule for Affective Disorders and Schizophrenia (SADS; 
Endicott & Spitzer, 1978)   and the National Institute of Mental Health (NIMH) 
Diagnostic Interview Schedule (DIS) (First, Spitzer, Gibbon, & Williams, 2002; Robins, 
Helzer, Croughan, & Ratcliff, 1981).   
 Eating Disorder Examination Questionnaire,(EDE-Q 6.0).  The EDE-Q 6.0  is a self-
report version (© 2008 by Christopher G. Fairburn and Sarah Beglin) of the Eating 
Disorder Examination (EDE) (Mond et al., 2004).  The EDE is a well-established semi-
structured interview designed to assess eating disorder psychopathology primarily 
occurring over the preceding four weeks (Fairburn & Cooper, 1993).  Two main areas of 
assessment include overeating and extreme methods of weight control.  The EDE-Q and 
the EDE are scored in the same fashion by including three types of descriptive data: 
scores on individual items, subscale scores, and a global score.  Two studies, both of 
which included over 100 patients with eating disorders, report the following range of 
alpha coefficients as a measure of subscale internal consistency: Restraint (.75-.78), 
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Eating Concern (.68-.78), Shape Concern (.70-.82), and Weight Concern (.68-.70) 
(Beumont, Kopec-Schrader, Talbot, & Touyz, 1993; Fairburn & Cooper, 1993).  
Preliminary norms for BN and CON groups from initial studies are published and 
available for comparison (Fairburn & Cooper, 1993).  Correlations between the EDE-Q 
and EDE subscales ranged from .68 for Eating Concern to .78 for Shape Concern.  Scores 
on the EDE-Q were significantly higher than those on the EDE for all subscales, with the 
mean difference ranging from .25 for Restraint to .85 for Shape Concern (Mond et al., 
2004).  The EDE-Q 6.0 was used during the screening visit as a diagnostic and 
descriptive measure of eating psychopathology.  For this study, the internal (Cronbach α) 
reliabilities for the EDE-Q subscales were as follows: restraint, 0.83; eating concerns, 
0.71; weight concern, 0.94; and shape concern, 0.97.   
 Restraint Scale, Revised.  The Restraint Scale, Revised (Polivy et al., 1988) is a 10-
item self-report multiple-choice questionnaire designed to measure chronic tendencies 
toward restrained eating.  The scale has two factors:  Concern for Dieting and Weight 
Fluctuations (Heatherton, Herman, Polivy, King, & McGree, 1988).  The revised scale is 
based on improvements made to the original version, with psychometric properties 
established following analysis of results from 166 male and 348 female college students 
(Polivy et al., 1988).  The scale demonstrates good internal reliability as determined by 
item-item and item-total correlations, and is unidimensional as confirmed by principal 
component analysis.  Orthogonal varimax rotation identified factors of the scale that 
demonstrate a reliable two-factor solution (Polivy et al., 1988) Test-retest reliability 
coefficients are as high as .93 when re-tested one week later. The median score for 
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female college students is 15-16.  Thus, individuals above this cut-off are likely to 
display more chronic restraint eating behavior than the other half of the population 
scoring below this threshold.  For this study, control subjects were included if their score 
< 16 on the Restraint Scale during the screening visit.  In the current sample, internal 
reliability was .93   
 Beck Depression Inventory®-II (Second Edition) (BDI-II).  The BDI -II is a 21-item 
self-administered rating scale designed to measure depressive symptoms.  Each item is 
rated on a four-point scale (Beck, Steer, & Brown, 1996). General scoring guidelines 
include the following categories: nondepressed / minimal depression (score of 0-13), mild 
depression (14-19), moderate depression (20-28), and severe depression (29-63).  
Content, construct, and factorial validity have been established.  The internal consistency 
alpha coefficient is .92 for outpatients and .93 for college students (Beck et al., 1996).  
The BDI-II was utilized at the screening and study visits to assess for level of depression 
and the need for clinical referral. The BDI-II was copyright © in 1996 by Aaron T. Beck 
and all rights are reserved.  The PI purchased each scale from Pearson Assessments 
http://www.pearsonassessments.com at an individual cost of $2.08 per scale.  In the 
current sample, internal (Cronbach α) reliability was 0.91.  
The Aggression Questionnaire.  The Aggression Questionnaire (Buss & Perry, 1992) 
is a 29-item self-administered rating designed to measure four factors: physical 
aggression, verbal aggression, anger, and hostility (resentment and suspicion).  The 
Aggression Questionnaire was constructed from the Buss-Durkee Hostility Inventory 
(Buss & Durkee, 1957) to measure components of aggression and improve the 
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psychometric properties of the earlier scale.  Psychometric properties are reported in 
three student cohorts totaling 1,253 individuals (Buss & Perry, 1992). Good internal 
consistency for the total scale is indicated by an alpha coefficient of .89.  Acceptable 
internal consistency of the subscales is suggested by the following alpha coefficients: .85, 
physical aggression; .72, verbal aggression; .83, anger; and .77, hostility.  Confirmatory 
factor analysis yielding similar coefficients was obtained in a sample of 306 college 
students (Harris, 1995).  Following a nine-week interval, test-retest correlations in 372 
students was .80 for the total scale and .72-.80 for subscales suggesting a relatively stable 
measure over time (Buss & Perry, 1992).  Self-report and peer nomination methods 
present strong evidence for construct validity of the physical aggression scale, while 
support for the construct validity of the other three subscales using this method appears 
modest (Buss & Perry, 1992). As previously stated, a baseline measure of aggression, 
utilizing the Aggression Questionnaire (Buss & Perry, 1992), was collected to obtain 
preliminary descriptive characteristics relative to anger and hostility. Cronbach α was 
0.89 in this sample.  A copy of the tool is available at: 
http://www.centralquestion.com/aggression/test.html 
Hunger, Satiety, Pleasantness of Foods Visual Analog Scales.  100mm visual analog 
scales (VAS) were used to assess subjective eating-related behavior.  The visual analog 
scale is easily administered and sensitive to incremental changes (Maxwell, 1978).  
Predictive validity of the hunger and satiety VAS is supported by observations of the 
predicted changes over time in response to food intake (Geracioti & Liddle, 1988; 
Hetherington & Rolls, 1987; Keel et al., 2007). In addition, changes in satiety are 
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associated with changes in plasma CCK (Keel, et al., 2007). However, changes in hunger 
have not been shown to be correlated with changes in plasma CCK—supporting the 
discriminant validity of the two measures for assessing different subjective experiences 
that have been linked to different physiological mechanisms (e.g., satiety to CCK and 
hunger to ghrelin) (Keel et al., 2007). Thus, these findings support construct validity of 
the concepts of hunger versus satiety. Because these measures are single-item 
assessments, which by definition will be less reliable than a multi-item assessment, 
internal consistency reliability was not examined.  The use of the pleasantness VAS was 
for the purpose of assessing acceptability of the test meal during acclimation procedures 
at the screening visit. In preliminary data on the pleasantness VAS at a single point 
following acclimation procedures to a test meal (on two different occasions), test-retest 
reliability was r (87)=.649, p<.001 (one-tailed) suggesting acceptable test-re-test 
reliability for the VAS for collecting subjective rating of a test meal [personal 
communication: Dr. Pamela Keel 7/24/07], Visual analogue scales have been validated 
and successfully applied to studies of eating behavior (Hetherington & Rolls, 1987).  
VAS ratings were obtained before and after the standardized liquid test meal.  
 Side Effect Checklist.  The Side Effect Checklist is a brief 22-item descriptive 
questionnaire in which adjectives are rated on a five point Likert Scale.  Subjects are 
asked to rate the extent to which the listed items are present "now."  Examples of items 
include headache, nausea, and stomach ache.  Response anchor points include "not at all," 
"a little," "moderately," "quite a bit," and "extremely."  The Side Effect Checklist has 
been used in previous studies (Wolfe, Metzger, & Jimerson, 1995; Wolfe et al., 2000).  
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This questionnaire was used before and after the standardized liquid test meal for 
monitoring of subjectively experienced side effects only. While not an outcome measure 
per se, a side effect checklist was included to monitor for any unanticipated effects and 
will be used for descriptive purposes. 
Study Procedure Considerations 
 The age range of 18-45 years old was chosen to reflect those individuals at greatest 
risk for and recurrence of the disorder.  The selected BMI range was chosen to reflect 
normal-weight states in order to minimize other potential physiologic confounders.  BN 
subjects were limited to those with purging (vomiting) subtype of BN, based on previous 
research (Devlin et al., 1997; Geracioti & Liddle, 1988; Phillipp, Pirke, Kellner, & Krieg, 
1991; Pirke et al., 1994) and high prevalence (Reba et al., 2005) allowing for comparison 
across studies.   
 While gastric size and emptying may play a role in CCK secretion, this project 
focused on first assessing the postprandial CCK response in persons with BN in 
remission for several reasons.  In the context of the hypotheses, it is important to first 
establish the functionality of CCK in persons with RBN.  Based on the intactness of the 
CCK responsivity to a test meal, several lines of inquiry resulted.  For example, there are 
several competing hypotheses regarding the possible etiology of altered CCK function in 
active BN including increased gastric capacity, reduced gastric relaxation, decreased 
gastric emptying, decreased CCK release, and other enteric autonomic function 
anomalies (Hadley & Walsh, 2003). Thus, to assess a single aspect of gastric functioning 
may pose significant limitations in the interpretation of findings.  To adequately address 
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these potential etiologic factors, a more comprehensive examination of gastric 
functioning would be needed and thus involve greater resources (e.g. radiology, 
gastroenterology) and invasive procedures.  However, this may be a potentially important 
follow-up study to the project. 
Protection of Human Subjects 
  Prior to the onset of this study, approval was obtained with an inter-institutional 
agreement between Boston College’s Institutional Review Board (IRB) and by the Beth 
Israel Deaconess Medical Center Committee on Clinical Investigations (CCI) - consent 
approval date 11/17/2010, protocol number 2009-000261.  This study also received 
“Protocol Approval” from BIDMC CRC Scientific Advisory Committee on 3/3/2010.  To 
protect confidentiality, study data were coded with a research subject number.  The code 
chart linking subject identification and number were stored separately in a locked file.   
 Study procedures were explained in depth, allowing subjects the time and opportunity 
to ask questions prior to signing the informed consent form.  Individuals with psychiatric 
disorders that might interfere with informed consent procedures (e.g., psychotic 
disorders) were not included in this study.  Subjects were monitored for symptoms of 
depression including active suicidal ideation.  Referral to a mental healthcare provider 
would have been made if appropriate. No such instances occurred during this study.  
 There was minimal risk of serious psychological harm from this study; however, 
individuals may have found the data collection forms and interviewing procedures to be 
tedious or stressful. These methods to gather data involved disclosure of sensitive and 
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personal information that may have been uncomfortable. Individuals who experienced the 
study procedures as stressful were allowed to withdraw.  Three such instances occurred.  
One individual was advised by her therapist not to participate.  Two individuals were 
concerned that they may become increasingly preoccupied by eating disordered behavior. 
Subjects may have found the taste of the standardized liquid test meal unpleasant; 
however, all individual rated the VAS for pleasantness (during the acclimation 
procedure) at or above the 50 percentile. While individuals may have been uncomfortable 
when consuming the drink over the requested five minute interval, none expressed 
discomfort.  Other rare side effects could have occurred (e.g., an allergic reaction to the 
standardized test meal drink).  All subjects were asked about any history of allergic 
reactions, including allergic reactions to foods, no reactions occurred. Blood drawing and 
placement of intravenous catheter in the arm could have caused localized discomfort, 
bruising or syncope. No individuals experienced related syncope or localized infections. 
The total volume of blood drawn did not exceed 50 mL.  Safety measures included 
careful diagnostic assessment, measurement of vital signs and side effect monitoring.  No 
adverse events occurred during this study. 
Informed Consent   
 During the screening visit, study procedures were carefully explained to the subjects.  
Questions were answered by the PI.  If a subject agreed to participate in the study, the 
consent form was signed by the subject, the investigator, and a witness.  The subject was 
given a copy of the informed consent form.  Consent was reviewed again with the 
subjects at the start of their study visit on the CRC, prior to the initiation of any study 
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procedures.  Additionally, the PI completed the “Responsible Conduct of Research” (see 
Appendix A) requirement by completing the CITI Program for Biomedical Research 
Investigators.   
Data Analyses and Sample Size 
H1. Subjects with BN will have a significantly blunted postprandial plasma CCK 
response compared to the RBN and CON groups.  The primary outcome measure, the 
CCK response, was calculated by the area-under-the-curve (AUC) utilizing the 
trapezoidal rule.  AUC is estimated by the cumulative (concentration versus time) CCK 
release during the duration of the standardized liquid test meal procedure.  A one-way 
ANOVA with a-priori-contrasts or planned comparisons was used to test for specified 
differences in the AUC response across the three study groups.  A one- tailed test was 
used because the a-priori hypothesis was directional, positing that the BN group’s 
response would be significantly blunted (decreased).  Additionally, the trapezoidal rule 
was utilized for all other AUC measurements. Sample size was based on the calculations 
described below.   
H2. Postprandial plasma CCK response will be significantly positively correlated 
with postprandial VAS measures of satiety in the RBN and CON groups.  To test this 
hypothesis, the relationship between postprandial CCK response (AUC) and visual 
analog ratings of satiety was assessed by using Pearson’s correlation coefficient.  Data 
not normally distributed were log transformed.   
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 Sample size calculations were based on the results reported by Devlin et al. (1997) for 
mean and standard error for CCK AUC response in patients with BN and controls (effect 
size d =1.45).  Based on these data a comparison of three groups with a planned sample 
size of 12 per group with alpha set at p=.05, two-tailed, results in a power of .8.
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CHAPTER 4 
RESULTS 
  All data were entered into a computerized data base and analyzed using the 
Statistical Package for Social Sciences (SPSS; version 19.0 for Windows; Chicago, IL). 
Descriptive statistics were calculated for all variables.  Frequency and distribution plots 
were examined to assess the normality distribution (skewness and kurtosis) and 
identification of outliers. Data not normally distributed were log transformed prior to 
analysis.   
The primary outcome measure, CCK response, was calculated by the area-under-
the-curve (AUC) utilizing the trapezoidal rule.  A one-way ANOVA utilizing a-priori 
contrasts (one-tailed) was used to test for differences in AUC between the three study 
groups.  Additionally, an ANOVA was utilized to compare groups prior to (baseline) and 
following ingestion (+15min.) of the standardized liquid test meal. 
The relationship between postprandial CCK response (AUC) and visual analog 
ratings of satiety (AUC) was assessed by using Pearson’s correlation coefficient. 
Additionally, AUC was calculated for the following VASs: satiety, fullness, hunger, and 
urge to binge and vomit.  The anchors for the satiety, fullness and hunger where 
represented as “not all” to “extremely”.  The anchors for binge and vomit ranged from 
“no urge” to “extreme urge.”  These data were utilized to assess for significant 
relationships and comparisons across groups for descriptive purposes. Group values were 
reported as mean ± standard deviation (SD).  A one-way ANOVA was used with an alpha 
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level of 0.05, two tailed to determine the probability for significant differences in groups 
descriptive (Table 2) and clinical characteristics (Table 3).  
 Fifty- six female volunteers were enrolled and met initial inclusion criteria for the 
study.  Subsequently, 41 subjects completed all study procedures. From those 41, four 
were excluded for the following reasons: two subjects were excluded due to significant 
outlier status (absolute z-score greater than 3.29); one disclosed she was taking an 
antibiotic after study procedures were completed; and nursing personnel reported 
(following the completion of study procedure) that one subject was administered 300ml 
versus 600ml of the standardized liquid test meal. Fifteen subjects who initially met 
inclusion criterion and completed the screening did not complete the study due to the 
following reasons: BMI < or > 19 – 26 kg/m2; fear of blood draw; unable to obtain blood 
sample; scheduling difficulties; and the three subjects that opted to drop out of study as 
previously stated in the Protection of Human Subjects Section.    
 Data from 37 subjects were included in the final analysis. There were no significant 
differences between subject groups age, weight, height, and BMI (p=ns; see Table 3).  
Overall sample mean ± SD age was 22.5±5.0 years and BMI 22.5±2.2 kg/m2.  The 
racial/ethnic composition of the sample participants was 71.1% white, 7.9% 
Black/African American, 18.4% Asian/Pacific Islander, 2.6% American Indian or Alaska 
Native, and 7.9% Hispanic, Latino or Spanish.  The racial/ethnic composition of these 
sample participants are consistent with the targeted/planned enrollment for this study and 
within the of the Boston area. 
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Table 2. Descriptive Characteristics-Comparison by Group 
 Mean±SD  
Measures Control RBN BN F 2, 34 
 n=13 n=14 n=10  
Age, yrs 21.0±1.9 22.4±4.1 22.2±3.5 .69 
Height, cm 163.5±6.9 165.5±5.5 164.3±6.3 .34 
Weight, kg 61.2±10.1 61.6±7.3 60.2±9.5 .07 
BMI,  kg/m2 22.7±2.7 22.4±1.8 22.1±2.3 .22 
Note. There were no significant differences among groups for age, weight, height, and BMI. 
 
 The average binge/purge frequency among the BN group was 19.7±10.9 per month 
and 4.9±2.7 per week, respectively.  For the RBN group, the average binge/purge 
frequency during active illness was 6.8 ± 4.6 per week.  There was no significant 
difference (t= -1.1, p=.81) in the average binge/purge frequency between the BN and the 
RBN groups during active illness.  The average illness duration in the BN group was 
4.3±3.9 years.  In the RBN group the average illness duration was 3.9±4.7 years and 
length of remission was 2.0±1.4 years.  Axis I disorders for the BN group included major 
depressive disorder (MDD), 10%; history of MDD, 10%; history of anorexia nervosa 
(AN), 50%; and the remaining 30% endorsed BN only. Those with history of AN were 
weight restored for a minimum of 2 years.  Axis I disorders for the RBN group included 
history of MDD, 36%; history of AN, 14%; substance use disorder (SUD); 14% and the 
remaining 36% endorsed previous diagnosis of BN only. The control group had no 
current or history of any Axis I diagnosis including eating disorders. 
 Table 3 presents comparisons on clinical questionnaires assessed at either the 
screening (EDE-Q and Herman & Polivy Restraint) or study visit (BDI-II and Aggression 
Scale).  The BN group scored significantly higher on the BDI-II scale, indicating 
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increased level of depression, in comparison to the RBN and CON groups. The BN group 
also rated significantly higher on measures of eating pathology in comparison to the RBN 
and CON groups.  For instance, the BN group scored significantly higher on global eating 
disorder severity, dietary restraint, and eating, weight, and shape concerns compared to 
the RBN and CON groups. Additionally, the RBN group scored significantly higher in 
comparison to the CON group on ratings of global eating disorder severity, weight and 
shape concerns and the total restraint scale. There were no significant differences among 
groups in overall Aggression Scale ratings. There was no significant correlation between 
aggression scores and CCK response within groups.  
Table 3. Clinical Characteristics - Comparison by Group 
 Mean (SD)   Mean± SD                    
Measures Control RBN BN F 2, 34 
EDE-Q n=13 n=13 n=10  
Global (subscales below)a .14±.39* 1.8± 1.8* 3.9± 1.2 21.67 
Restraint .48± .69* 1.5± 1.6* 3.3± 1.3 14.60 
Eating concern .14± .39* 1.4± 1.7* 3.9± 2.5 14.22 
Weight concerna .38± .47* 1.9± 1.9* 4.1± 1.4 18.52 
Shape concerna .63± .61* 2.2± 2.1* 4.7± 1.2 21.82 
Binge/Purge (last 28 days) N/A N/A 19.6+ 9.7   
BDI-II 1.3± 1.1* 1.7± 2.7* 15.5± 11.4 17.65 
Herman& Polivy Restrainta   5.6± 3.3* 14.3± 8.5* 21.4± 5.5 18.20 
Aggression Scale (Total) 49.6± 11.7 58.8± 19 59.9± 13.8 1.67 
Note. EDE-Q=Eating Disorder Examination-Questionnaire; BDI-II= Beck Depression Inventory- II  
*Significantly different than BN group: p < .05, two-tailed, after Bonferroni adjustment.  
aThe RBN group is also significantly different than CON group: p < .05,  two-tailed, after Bonferroni 
adjustment. 
 
 
 
 
                                                                                                                            44   
 
H1. Subjects with BN will have a significantly blunted postprandial plasma CCK 
response compared to the RBN and CON groups.   
CCK response, as measured by AUC, tended to be lower in the BN group 
(M=1.77± .60) compared to the RBN group (M= 2.01± .41) and the CON group (M= 
3.13±.47).  The assumption of homogeneity of variance was met (p =.35).  Planned 
contrasts revealed a significant linear trend, F2,34 = 3.07, p < .05 (one-tailed), indicating 
that CCK response increased from the BN, RBN and CON groups respectively.  Planned 
contrasts revealed that the BN group’s CCK response approached a significant difference, 
t (34) = 1.67 (p=.052, one-tailed, f = .30) in comparison to the RBN and CON. Therefore, 
this hypothesis was not supported, although a trend was observed.  The second planned 
comparison revealed no significant difference, t (34) = 1.67 (p=.27, one-tailed) between 
the RBN and the CON groups.  There was a significant within-subjects effect over time 
(F=19.34, df = 3, p= .000) between all groups, before (baseline) and after (+15min.) the 
ingestion of the standardized liquid test meal.  
 
Table 4.  CCK Response by Group Mean 
Mean ± SD 
 
Baseline +15min +30 +60 
Control 0.145 4.24 ± 2.9    3.29±3.6  4.44±4.1 
RBN 0.145 2.59 ± 2.7 2.68±2.5 2.98±2.1 
BN 0.145 2.33 ± 2.7 2.15±3.1 1.78±1.2 
 
Mean CCK concentrations and standard errors of estimates across time points for 
all groups are depicted in Figure 6.  
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Figure 6. Group mean values of CCK concentrations at each time point before and after the 
standardized liquid test meal.  The mean standard error of estimates at each time point is 
presented. 
 
 
 
H2. Postprandial plasma CCK response will be significantly positively correlated with 
postprandial VAS measures of satiety in the RBN and CON groups. 
  Satiety was measured on 100mm VAS that ranged from “not at all satiated” to 
“extremely satiated.”  A significant positive relationship exists between CCK (AUC) 
response and ratings of satiety (AUC) in the RBN group only.  Those subjects in the 
RBN group that had a more robust CCK response rated higher levels of satiety  
(r = .58, p < .05).   
Additionally, a significant positive relationship exists between CCK (AUC) 
concentrations and the RBN group ratings of fullness (r = .54, p <.05).  Fullness (AUC) 
and satiety VASs were significantly correlated in the BN (r = .74, p <0.05), RBN (r = .73, 
p <0.01), and CON (r = .71, p <0.01) groups.  Thus, in all groups, as ratings of satiety 
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increased, subjective ratings of fullness also increased. Increased CCK (AUC) response 
in the BN group was significantly correlated (r=.86, p < .01, two-tailed) with urge to 
vomit.  In the BN group, those who had increased CCK responses reported a greater urge 
to vomit.  
There was a significant difference between the BN and CON (AUC) groups in 
“urge to binge” (F2,34 = 6.26, p < .01), and “urge to vomit” (F2,34 = 6.47, p < .01), after 
log transformation and Bonferroni correction (Figure 6) but not in the RBN (AUC).   The 
BN group reported the greatest urge to binge (M=2.8±.76) compared to the RBN 
(M=2.2±.85) and the group that reported the least was as expected the CON (M=1.6±.72).  
Similarly, the BN group reported the greatest urge to vomit (M=2.9±.96) compared to the 
RBN (M=2.4±.85).  Again the CON group reported the least (M=1.6±.89) as expected.  
Figure 7 shows that the BN group’s ratings for “urge to binge” did not change or respond 
differently from before to after the test meal.  In contrast, the RBN and CON groups had 
decreased “urge to binge” following the ingestion of the test meal.  
After the ingestion of the test meal both the RBN and the CON groups responded 
with a modest elevation in “urge to vomit” and steadily declined afterwards.  The BN 
group had an initial sharp increase in “urge to vomit” following ingestion of the test meal 
and then plateaued for the remaining time points (Figure 7).    
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Figure 7. The mean group comparison of subjective eating related responses (VAS measured as 
100mm) to the standardized test meal.  
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Figure 8. The mean within-group comparison of subjective eating related responses 
(VAS measured as 100mm) to the standardized test meal. 
 
0
10
20
30
40
50
60
70
80
90
100
Baseline 15 30 60
C
on
tr
ol
 
Time (min) 
Satiated
Fullness
Hungry
Binge
Vomit
0
10
20
30
40
50
60
70
80
90
100
Baseline 15 30 60
B
ul
im
ic
 
Time (min) 
Satiated
Fullness
Hungry
Binge
Vomit
0
10
20
30
40
50
60
70
80
90
100
Baseline 15 30 60
R
em
it
te
d
 
Time (min) 
Satiated
Fullness
Hungry
Binge
Vomit
                                                                                                                      50 
 
 
 
CHAPTER 5 
 
DISCUSSION 
 
 
 To this investigator’s knowledge, this is the first study to compare postprandial CCK 
response and subjective ratings of satiety from a group of individuals who have remitted 
from bulimia nervosa (RBN) to those with the active illness (BN) and healthy controls 
(CON).   Previous studies found that CCK, a satiety producing hormone, is decreased in 
BN in comparison to healthy CON (Devlin et al., 1997; Keel et al., 2007).  These 
previous results inferred that a decreased CCK response may be a possible cause, 
consequence, and or maintenance factor for binge eating in individuals suffering from 
BN.   Therefore, it was unknown whether CCK response returns to normal after 
individuals recover from this illness. This gap in knowledge hinders our understanding 
and ability to develop effective treatment strategies.  
  The purpose of this study was to assess whether postprandial CCK response 
normalizes following remission from BN and if CCK responsivity correlates with 
subjective ratings of satiety in the RBN and CON groups.  Based on theoretical grounds, 
the assumption was that the binge and / or purge processes and the subsequent 
compilation of gastrointestinal dysfunctions may disrupt the endogenous signal pathway 
to the hindbrain and alter the potency of the negative feedback system.  When there is a 
dysregulation in the potency of this feedback system, meal size and duration can be 
increased.  
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Postprandial CCK Response 
 In this study, the BN group’s postprandial CCK level was lower (approached 
significance at p =.052) than both the RBN and CON groups.  As anticipated, the RBN 
and the CON groups’ CCK response did not significantly differ from each other.  This 
finding was expected and supports the premise that CCK response may normalize 
following abstinence from binge and purge episodes.  In this study, remission from 
episodes ranged from nine months to six years and there was no significant correlation in 
this RBN group’s CCK response with time since their last binge/purge episode.  While 
these results do not offer particular guidance concerning when CCK response begins to 
normalize, it does indicate that previous findings of a blunted response in the BN 
population may be a state versus trait related phenomenon.  
 While the BN group’s CCK response approached significance, it was not statistically 
significantly different from CON as observed in previous studies (Devlin et al., 1997; 
Keel et al., 2007).   In comparison to the Devlin (1997) study, this discrepancy may be 
accounted for by differences in the BN subjects’ characteristics.  For example, in the 
Devlin (1997) study BN subjects reported two times as many (10.3 ± 4.3) binge/purge 
episodes per week in comparison to that observed in the current study (4.9 ± 2.7).  
Participants in the Devlin (1997) study reported an average duration of illness of 9.8 ± 
1.9 years and their BN group was recruited from inpatient or outpatient treatment 
settings.  In this study, the BN subjects reported their average duration of illness to be 
half that amount (4.3± 3.9) and none endorsed being in treatment or intending to engage 
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in treatment.  Therefore, in this study, these BN subjects may be healthier sub-group that 
does not suffer the degree of physiological dysregulation. 
  In this study, in comparison to the Keel (2007) study, the clinical characteristics of 
the BN groups’ were similar in BMI, on binge/purge frequency, EDE and BDI-II scores.  
Illness duration was not indicated in the Keel (2007) report.  However, in the Keel (2007) 
study the BN group (n=34) was much larger than this study (n=10).  Thus, a larger BN 
group may have revealed a significant physiological difference between study groups.  
To replicate this study in the future and ensure an adequate sample size, calculations 
conducted using G-Power © 1992-2010 (Faul, Erdfelder, Lang, & Buchner, 2007) found 
that using the current medium effect size (f=.30) with an alpha set at p=.05, power of .80, 
one tailed, that an adequate number of study participants is N=89 or approximately a BN 
group of n=30.   
Biobehavioral Responses to Test Meal 
This is the first study to examine the relationship of the biological CCK 
responsivity to behavioral ratings of satiety and other eating related sensations in those 
who have remitted from BN.  Previous biobehavioral studies have found postprandial 
visual analog satiety ratings to be positively correlated with CCK responses in healthy 
males (Holt et al., 1992).  Another investigator showed  that using a liquid test meal 
significantly stimulated CCK release and correlated with increased fullness ratings in 
healthy males and females (Nolan et al., 2003).  Yet, another eating disorder study found 
a positive relationship when examining CCK and satiety responses (Keel et al., 2007).  
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  In this study, only the RBN group had a significant positive relationship between the 
postprandial CCK (AUC) response with satiety and fullness ratings.  In contrast, the BN 
and CON groups’ CCK response did not correlate with satiety ratings.  This latter finding 
does replicate other previous studies (Devlin et al., 1997).   
 However, overall there is conflicting evidence whether those with BN are able or 
unable to accurately detect eating related sensations (including satiety) postprandially. In 
an effort to better understand eating related sensations, a recent study measured and 
compared the satiety responses to a fixed one-item liquid test meal in those with BN and 
healthy controls (Zimmerli, Devlin, Kissileff, & Walsh, 2010). This study found no 
differences in ratings of fullness or hunger at the beginning, end or over the course of the 
meal between the BN and CON groups (Zimmerli et al., 2010).  While these investigators 
were surprised by these findings, they concluded that when BN subjects are given a fixed 
meal they tend to report the same subjective findings of satiety and related sensations 
than controls (Zimmerli et al., 2010).  These investigators further noted that previous 
studies, (Kissileff et al., 1996) using ad-libitum versus fixed meals were able to detect 
differences in satiety and other eating related sensations between BN and CON groups.   
In previous studies, BN subjects report feeling less, rather than more, satiated, 
after eating excessively large amounts of food.  In sharp contrast to healthy controls, 
despite eating quantifiably larger amounts of food, patients with BN reported less fullness 
and displayed increased motivation to eat as the meal progressed (Kissileff et.al, 1996). 
When those with BN are given an unlimited amount of a liquid test meal to consume 
(more accurately depicting a binge episode) their sensations of satiety are disturbed 
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(Kissileff et al., 1996).  In this study, participants were allowed to drink 900 kcal in an 
effort to compare across groups and previous studies.  However, this fixed meal approach 
may be a limiting factor in accurately measuring eating related sensations in those with 
BN.  
  In the present study, the RBN group had the largest mean satiety ratings in 
comparison to the BN and CON groups.  There is also a significant positive relationship 
between the biological CCK response and the behavioral satiety and fullness ratings in 
this group.  Perhaps this positive relationship decreases the vulnerability and increases 
the success of this group in abstaining from binge eating behavior.  CCK concentrations 
may become a helpful biomarker of satiety and harbinger of abstinence from these 
unhealthy behaviors.  
 In the RBN group, perhaps CCK receptors on the vagus nerve up-regulate and allow 
for more opportunities for signal transmission to the hindbrain.  This up-regulation might 
occur when higher order signals, while interpreting metabolic status, detect a deficiency 
in signal transmission (Faris et al., 2008). In an attempt to maintain homeostasis, a 
mechanism in the hypothalamus may modulate a shift in lower order signaling, resulting 
in an improvement in the potency of the negative feedback system (Dockray, 2009).  In 
the BN group, an alternative explanation may be that this homeostatic process is ignored 
(desensitized) by the hypothalamus and the hind brain.  This may occur due to the 
abnormally increased activity of the vagus nerve (chronic and repetitive binge and vomit 
behavior) resulting in abnormal transmission (Faris et al., 2008). 
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 Interestingly, a new finding from this current study was the positive correlation 
between the BN groups’ CCK response and urge to vomit following the ingestion of the 
standardized liquid test meal.  In the BN group, those with larger CCK responses reported 
the greatest urge to vomit.   Perhaps those in the BN group become sensitive or 
uncomfortable to the sensations associated with the release of the satiety hormone, 
triggering an episode of vomiting, and subsequent feeling of relief from this negative 
experience. There are lines of inquiry that question the afferent vagus nerve in its dual or 
parallel function of signaling satiety and the vomit (emetic) response (Faris et al., 2008).  
Perhaps due to the abnormal vagal afferent activity of those with BN, these circuits 
become overloaded resulting in misinformation and vomiting behavior.  
In a group of individuals with purging disorder (PD), individuals who don’t 
engage in typical binge eating behavior but vomit following ingestion of smaller amounts 
of food, CCK responsivity and urge to vomit were statistically greater than for those with 
BN (Keel, 2007).   Additionally, the CCK response in the PD group was not significantly 
different than healthy controls. In comparison to the new results from this current study, 
perhaps the PD group is also sensitive to elevations in CCK concentrations.   Potentially, 
this proposed sensitivity becomes expressed in vomiting behavior.  
Another interesting association to the Keel (2007) study is the VAS of eating 
related sensations pre and post ingestion of the standardized liquid test meal.  The ratings 
from both studies are similar for fullness, hunger, urge to binge, and vomit in the BN and 
the CON groups respectively.  This suggests reliability in the manner in which these 
constructs are measured (VAS) and the validity of doing so within these populations.      
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In the present study, besides scoring significantly higher than CON on global 
eating disorder severity, the RBN continued to report both urge to binge and vomit 
without engaging in those behaviors.  The RBN group reported fewer urges than that of 
the BN groups but greater than the CON groups across all time points. These ongoing and 
persistent urges are cause for concern as they may increase the vulnerability of these 
individuals to relapse.  
Implications for Theory, Research, and Practice 
The current study supports the theory that CCK responsivity normalizes when 
individuals have remitted from this illness.  Therefore, in concert with the model 
presented in chapter two, there may be an adaptive response that recalibrates and begins 
to effectively regulate and control the input of neuronal and hormonal signals to the hind 
brain.  As a result, homeostasis and the stability of the hormone system loops are 
restored.  The resulting output responses are the absence of these debilitating behaviors 
(binge/vomit). What is unclear is which adaptive mechanism(s) must be present and 
properly functioning for CCK responsivity to return to normal and for this behavior to 
remit.  Understanding what biological or behavioral adaptations must occur before 
remission and how these can be promoted and maintained is essential to the development 
of effective treatment strategies, relapse prevention, and merits further investigation.     
 Replication of the findings from this study using a larger sample size (increasing 
statistical power) are needed to gain a better understanding of the process and temporal 
factors associated with the normalization of CCK responsivity in RBN.  For instance, 
with a larger sample size researchers can examine whether there are relationships among 
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previous frequency of binge/vomit episodes, duration of illness, length of remission, 
CCK responsivity, and eating and satiety related behavioral responses to test meals. 
 To gain a comprehensive understanding of the complex physiological interactions 
that effect or have an effect on abstinence and relapse prevention, studies are needed to 
evaluate the relationships between CCK and other dysregulated anorexigenic (e.g., GLP-
1, PYY) or orexgenic (e.g. ghrelin) peptides (Monteleone, Martiadis, Fabrazzo, Serritella, 
& Maj, 2003; Munsch, Biedert, Meyer, Herpertz, & Beglinger, 2009) and eating related 
pathways (Broft, Berner, Martinez, & Walsh, 2011). Emphasis should be focused on 
research that explores pharmacotherapeutic agents that may have an effect on increasing 
CCK levels (e.g. SSRI’s, antibiotics, probiotics, and prebiotics).  It would be informative 
to evaluate if increased CCK levels would decrease binge/vomit behaviors and or 
increase urge to vomit in those with BN.   
A previous double blind placebo controlled study reported a significant decrease in 
binge/vomit behavior in a BN group when administered ondansetron (anti-emetic) 
compared to placebo (Faris et al., 2006). These investigators contend that the stabilization 
of the vagus nerve is the rationale for efficacy.  Initially this treatment was not considered 
a viable option in part due to the multiple daily doses of this costly medication, lack of 
FDA approval for this indication, and thus insurance companies denied to cover its cost 
(Faris et al., 2008).  However, currently this medication is available in generic form and 
may become a feasible treatment option and future line of investigation.  
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 Further practice implications include a clinician’s careful assessment of the frequency 
of binge and vomit episodes, factors that may perpetuate or maintain this behavior, 
duration of illness, current motivation, and commitment to treatment and the recovery 
process.  The practicing clinician should provide psycho-education concerning the 
current etiology, pathophysiology (e.g. dysregulated neuroendrine responses), 
vulnerability factors for relapse or obstacles to recovery.  Those who have remitted from 
this illness should be aware of current urge to binge/vomit, personal triggers, residual 
eating disordered thinking and abnormal eating patterns.  Clinicians should discuss 
potential neuroendrocrine protective (e.g. CCK) responses and liability (e.g., residual 
eating disordered behaviors) factors that may increase patients’ vulnerability to relapse or 
strengthen their road to a fully functional recovery. 
 
Limitations 
 A small sample size may have failed to detect a significant difference between the 
BN, CON, and RBN groups CCK responsivity to a standardized liquid test meal.  Due to 
the lower frequency of binge/vomit episodes in this study in comparison to others, these 
findings may not generalize to a more symptomatic population.  The inclusion/exclusion 
criterion limited to purging (vomiting-type) only. Study participants self-reported their 
frequency of binge/purge behavior; therefore, unable to verify accuracy. Study 
participants may not have fully understood the term satiety in reference to the VAS.  Also 
because the subjects answered identical VAS and SEC at 4 time points during the study 
visit, their responses may have been affected due to this factor.  In this study, all 
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participants were asked to drink a standardized liquid test meal in an effort to compare 
across groups and previous studies.  However, this may have been a limiting factor in 
accurately measuring eating related sensations in those with BN and RBN.   
Summary and Conclusions  
Results extend the understanding of the postprandial CCK response in those who 
have remitted from BN.  The implications of this study are that CCK responsivity 
normalizes in those who remit from binge and vomit behavior.  While this study does not 
offer particular guidance concerning when CCK response begins to normalize, it does 
indicate that previous findings of a blunted response in the BN population may be a state 
versus trait related phenomenon.  The findings from this study also suggest that those 
with active illness who have increased CCK concentrations experienced greater urges to 
vomit.  Investigators are left to determine if this relationship also exists when 
pharmacotherapeutic agents are given that may enhance CCK functioning.  Therefore, 
will the normalization of CCK functioning prove to be a protective or liability factor in 
the stabilization and recovery of BN? Future studies in these lines of inquiry will help 
elucidate effective treatment strategies aimed at obtaining and maintaining full recovery 
from BN.      
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WHY THIS STUDY IS BEING DONE 
This study is designed to increase our understanding of bulimia nervosa.  Individuals with 
this syndrome often binge eat and then purge their food.  While emotional problems 
appear to be key in understanding this disorder, some changes in the natural hormones 
that influence meal patterns may play a role in these conditions.  This study involves 
standard interviews, questionnaires and blood hormone measurements in women who 
currently have bulimia nervosa, recovered from bulimia nervosa, and in healthy female 
volunteers with normal eating patterns.  An overall goal of the study is to help assess 
whether changes in the blood levels of the naturally occurring hormone cholecystokinin 
(CCK) adds to the continuation of this eating disorder. 
 
WHO WILL PARTICIPATE IN THE STUDY 
Approximately 45 people will take part in this study at Beth Israel Deaconess Medical 
Center.  You are invited to participate in this research study as an individual with bulimia 
nervosa, someone who has recovered from bulimia nervosa, or as a healthy volunteer.  
Your participation is completely voluntary; you are free to withdraw from the study at any 
time. 
 
WHAT WILL HAPPEN DURING THE STUDY 
If you agree to be in this study, you will be asked to read and sign this consent form.  After 
you sign the consent form, the following things will happen: 
 
1. Screening Procedures:  Screening procedures are tests and procedures that will be 
done to determine if you are eligible to take part in the research study.  For this 
research study, the screening procedures include the following:   
 During the screening visit (to occur at Boston College or BIDMC), you 
will receive a detailed explanation of study procedures, indicate that you 
understand the nature of these procedures, are willing to participate, and 
have the opportunity to ask questions prior to signing this consent form.  
 You will be asked to participate in an interview and complete 
questionnaires regarding your usual eating patterns and any past or 
current emotional problems.   
 During this visit, if you qualify, you will learn about the details of the 
second part of the study to occur at BIDMC.  This involves the 
measurement of blood hormone levels after you drink a nutritional shake 
(test meal drink).   
 You will be able to sample the shake used during the screening visit. 
   
2.  Research Procedures:  If you qualify to take part in this research study, you will 
undergo these research procedures:   
 The study visit (which may last approximately two hours) is usually 
scheduled within two weeks of the screening visit and takes place in the 
General Clinical Research Center (GCRC) at Beth Israel Deaconess 
Medical Center.   
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 Prior to the visit to the GCRC, you will have been asked not to eat or 
drink anything from 11 PM the previous evening until you arrive for the 
study visit the next morning.  
 After review of this consent form, you will have your height, weight, 
blood pressure, pulse and temperature measured. You will also be asked 
questions about any past or current medical problems.  
 You will have a small plastic tube (catheter) placed in a vein in your 
forearm with a needle.  The tube will be taped in place and will remain 
there until the study visit is over.   
 You will be asked to complete a side effect checklist and questionnaires 
that ask you questions related to your mood, appetite, and any symptoms 
you may be feeling. You will be asked to drink a nutritional shake 
(approximately 600ml/900 calories) over a five minute period. 
  Blood samples will be collected before you drink the shake, and +15 , 
+30, and +60 minutes after you drink the shake.  
 
 
POSSIBLE RISKS, SIDE EFFECTS, AND DISCOMFORTS 
 
RISKS OF THE RESEARCH STUDY 
As a result of your participation in this study, you are at risk for side effects listed in this 
section.  You should discuss these with the investigator and with your regular health care 
provider if you choose. 
 
The total amount of blood drawn for this study will be approximately 50 ml, which is 
slightly less than two ounces.  The risks and discomforts of blood drawing from a vein 
include the possibility of pain or bruising at the site of the blood draw; occasional feeling 
of lightheadedness; and rarely, infection at the site of the blood draw.  You may find that 
the nutritional shake does not taste pleasant, or that it may be uncomfortable to consume 
the drink over the requested five minutes.  
 
LOSS OF CONFIDENTIALITY 
There is the potential for loss of confidentiality by participating in this study.  Every 
effort will be made to protect the confidentiality of your identifiable information.  All 
information will be coded by a research number and will be stored in secure filing cabinet 
and office space in the Center for Nursing Research at Boston College.  However, if your 
participation becomes known, it could create a problem or hardship for you depending 
upon the type of information disclosed.   
 
PSYCHOLOGICAL STRESS: 
Some of the questions we will ask you as part of this study may make you feel 
uncomfortable. You will be asked to complete and participate in sometimes long and 
personal questionnaires and interviews in a total of two visits. You may refuse to answer 
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any of the questions and you may take a break at any time during the study.  You may 
stop your participation in the study at any time. 
 
POSSIBLE BENEFITS 
There is no direct benefit to you from being in this study.  However, your participation 
may help others in the future as a result of knowledge gained from the research. 
 
OTHER AVAILABLE OPTIONS 
Taking part in this study is voluntary.  Your alternative is to not participate in the study.  
You should not consider participation in this study as a substitute for mental health 
therapy or treatment.  You will be provided with care to help you feel more comfortable 
and information regarding mental health clinics or professionals can be provided to you if 
you wish.  We recommend that you discuss these and other options with the investigator 
and your regular healthcare provider so that you can make a well-informed decision 
about participating in this study. 
 
IF YOU DECIDE NOT TO TAKE PART IN THE STUDY 
Participation in this study is voluntary.  You have the right to decide not to take part in 
this study.  If you choose to participate, you have the right to leave the study at any time.  
However, please be aware that there may be risks to leaving the study before it has been 
completed.  If you decide not to participate in the study or decide to leave the study early, 
your decision will not affect your relationship with your health care provider or with Beth 
Israel Deaconess Medical Center.   
 
The investigators have the right to end your participation in this study if they determine 
that you no longer qualify to take part, or if it would be dangerous for you to continue, or 
if you do not follow study procedures as directed by the investigators.  Beth Israel 
Deaconess Medical Center or the funding source may stop the study at any time. 
 
 
INVESTIGATORS RIGHT TO STOP THE STUDY 
The investigators have the right to end your participation in this study if they determine 
that you no longer qualify to take part, or if it would be dangerous for you to continue, or 
if you do not follow study procedures as directed by the investigators.  Beth Israel 
Deaconess Medical Center or the funding source may stop the study at any time. 
 
COSTS AND/OR PAYMENTS TO YOU 
You will be paid a total of $100 over the study period.  You will receive thirty- dollars 
($30) at the completion of the screening visit and seventy ($70) at the completion of the 
study visit.  You will also be given parking vouchers for each visit. 
 
COSTS COVERED BY STUDY 
You will not be charged for any tests or procedures that are part of this research study.   
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PAYMENTS TO YOU: 
Any payments made to you may be taxable income to you. This does not include any 
payments you may receive to reimburse (pay you back) you for certain expenses like 
parking fees or travel.  We are required to obtain your name and social security number 
for preparation and submission of Internal Revenue Service (IRS) Form 1099-Misc.  You 
may receive an Internal Revenue Service Form 1099 from BIDMC if you receive more 
than $600 or more in one calendar year for taking part in one or more research studies at 
BIDMC.  Questions about your own tax status should be referred to your personal tax 
advisor. 
 
COST OF RESEARCH RELATED INJURY: 
If you are injured as a direct result of your participation in this study, you should contact 
the Investigator at the number provided under the section “Who to Call if You Have 
Questions” in this form.  You will be offered the necessary care to treat your injury. We 
reserve the right to bill your insurance company or the sponsor, if appropriate, for the 
care you get for the injury. We will try to get these costs paid for, but you may be 
responsible for some of them. You may be responsible for all co-payments and 
deductibles required under your insurance.  At this time there is no plan to reimburse you 
for items such as lost wages or lost time from work. By signing this consent form you 
have not given up any legal rights. 
 
CONFIDENTIALITY 
Information learned from your participation in this study and from your medical record 
may be reviewed and photocopied by the Food and Drug Administration (FDA) and/or 
other federal and state regulatory agencies, accreditation agencies, the Committee on 
Clinical Investigations and the Human Subjects Protection Office of the Beth Israel 
Deaconess Medical Center with protection of confidentiality so far as permitted by 
applicable law.  Information resulting from this study and from your medical record may 
be used for research purposes and may be published; however, you will not be identified 
by name in such publications. 
 
AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR PROTECTED 
HEALTH INFORMATION 
As part of this study, we will be collecting and sharing information about you with 
others.  Please review this section carefully as it contains information about the federal 
privacy rules and the use of your information.   
 
PROTECTED HEALTH INFORMATION [PHI] 
By signing this informed consent document, you are allowing the investigators and other 
authorized personnel to use [internally at BIDMC] and disclose [to people and 
organizations outside the BIDMC workforce identified in this consent] health information 
about you.  This may include new information generated as part of this study through 
questionnaires, tests, procedures we may ask you to undergo.  This is your Protected 
Health Information. 
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PEOPLE/GROUPS AT BIDMC WHO WILL USE YOUR PROTECTED HEALTH 
INFORMATION 
Your Protected Health Information may be shared with investigators listed on this 
consent form as well as the supporting research team [i.e. research assistants, statisticians, 
data managers, laboratory personnel, administrative assistants].  Your Protected Health 
Information may also be shared with the Committee on Clinical Investigations of Beth 
Israel Deaconess Medical Center as it is responsible for reviewing studies for the 
protection of the research subjects. 
 
PEOPLE/GROUPS OUTSIDE OF BIDMC WITH WHOM YOUR PROTECTED HEALTH 
INFORMATION WILL BE SHARED 
We will take care to maintain confidentiality and privacy about you and your Protected 
Health Information.  We may share your Protected Health Information with the following 
groups so that they may carry out their duties related to this study: 
 
 The funding source of this study NINR and NIH and their clinical research 
organizations 
 Research collaborators from the William F. Connell School of Nursing at Boston 
College 
 The Food and Drug Administration [FDA], the Department of Health and Human 
Services [DHHS], and the Office for Human Research Protections [OHRP]  
 Hospital and Clinical Research Accrediting Agencies 
 
Those who receive your Protected Health Information may make further disclosures to 
others.  If they do, your information may no longer be covered by the federal privacy 
regulations. 
 
 
WHY WE ARE USING AND SHARING YOUR PROTECTED HEALTH INFORMATION 
The main reason for using and sharing your Protected Health Information is to conduct 
and oversee the research as described in this Informed Consent Document.  We also shall 
use and share your Protected Health Information to ensure that the research meets legal, 
institutional and accreditation requirements and to conduct public health activities. 
 
NO EXPIRATION DATE – RIGHT TO WITHDRAW AUTHORIZATION 
Your authorization for the use and disclosure of your Protected Health Information in this 
Study shall never expire.  However, you may withdraw your authorization for the use and 
disclosure of your Protected Health Information at any time provided you notify the 
Principal Investigator in writing.  If you would like to take back your authorization so 
that your Protected Health Information can no longer be used in this study, please send a 
letter notifying the Principal Investigator of your withdrawal of your authorization to 
Sandy Hannon-Engel at 140 Commonwealth Ave, Chestnut Hill, MA 02467.  Please be 
aware that the investigators in this study will not be required to destroy or retrieve any of 
                                                                                                                      83 
 
your Protected Health Information that has already been used or disclosed before the 
Principal Investigator receives your letter. 
 
REFUSAL TO SIGN 
If you choose not to sign this informed consent document and authorization for the use 
and disclosure of your Protected Health Information, you will not be allowed to take part 
in the research study. 
 
RIGHT TO ACCESS AND COPY YOUR PHI 
If you wish to review or copy your Protected Health Information as it is made part of 
your medical record, you may do so after the completion or termination of the study by 
sending a letter to the Principal Investigator requesting a copy of your Protected Health 
Information.  You may not be allowed to inspect or copy your Protected Health 
Information until this study is completed or terminated. 
 
NOTICE OF PRIVACY PRACTICES 
In addition to signing this document, you may also be asked to sign a BIDMC General 
Agreement form acknowledging that you have received the BIDMC Notice of Privacy 
Practices. 
 
WHOM TO CALL IF YOU HAVE QUESTIONS OR PROBLEMS 
If you have any questions about this research or experience any problems, you should 
contact Sandra Hannon-Engel at [508] 274-0671.  You may contact the Human Subjects 
Protection Office at [617] 667-0469 in the event that you would like to obtain 
information or to offer input about the research study. This office is independent of the 
investigator or investigator’s research staff and can also assist with questions relating to 
your rights as a participant in research, which may include questions, concerns or 
complaints about your participation in the study. 
 
THE FOLLOWING PARAGRAPHS CONTAIN SOME STANDARD 
INFORMATION WHICH GENERALLY APPLIES TO INDIVIDUALS 
PARTICIPATING IN A RESEARCH STUDY. 
 
CONSENT FORM FOR CLINICAL RESEARCH 
 
I have read the previous page[s] of the consent form and the investigator has explained the details 
of the study.  I understand that I am free to ask additional questions. 
 
If I wish additional information regarding this research and my rights as a research subject, or if I 
believe I have been harmed by this study, I may contact the Human Subjects Protection Office 
(HSPO) at [617]667-0469 
 
I am aware that this is a research project and that unforeseen side effects may occur. 
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I understand that the Beth Israel Deaconess Medical Center has no formal program for 
compensating patients for medical injuries arising from this research.  Medical treatment will be 
provided for injuries at the usual charge to me or to my insurer unless payment is otherwise 
provided from this consent form. 
 
I understand that participation in this study is voluntary and I may refuse to participate or may 
discontinue participation at any time without penalty, loss of benefits, or prejudice to the quality 
of care which I will receive. 
 
I acknowledge that no guarantees have been made to me regarding the results of the treatment 
involved in this study, and I consent to participate in the study and have been given a copy of  
this form. 
 
 
WITNESS    DATE        STUDY SUBJECT     DATE 
 
 
PARENT /OR LEGAL GUARDIAN      DATE   
[If subject is a minor, or subject is unable to give consent) 
 
The subject has been given the opportunity to read this consent form and to ask questions  
before signing, and has been given a copy. 
 
     
 ___________________________________________________________ 
  SIGNATURE OF INVESTIGATOR/Co-Investigator   DATE 
 
     
 __________________________________________________________ 
  PRINT INVESTIGATOR’S/CO-Investigator 
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